Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus: Five of eight analysts rate Corcept Therapeutics a buy, with an average 12-month price target of $138.17 versus a recent price of $114.86.
• Recent results and growth prospects were strong: Quarterly earnings reached $0.36 per share versus $0.02 expected, while revenue rose 31.7% year over year to $256.15 million. Korlym sales growth and the Lifyorli launch are expected to support future expansion.
• Valuation and insider selling present risks: The stock trades at a very high P/E ratio of 273.48, and insiders have sold about $50.6 million of shares over the past 90 days, despite institutional investors owning 93.61% of the company.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $138.1667.

Several brokerages have commented on CORT. Wall Street Zen upgraded Corcept Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Piper Sandler reiterated an "overweight" rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a report on Thursday, May 28th. Weiss Ratings lowered shares of Corcept Therapeutics from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, September 8th. Finally, Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple EPS forecasts: Estimates increased for Q4 2026 to $0.68 from $0.62, Q3 2027 to $0.78 from $0.66, FY2027 to $2.05 from $1.91, and FY2028 to $4.31 from $4.07. The upward revisions suggest improving expectations for Corcept’s long-term earnings growth. Zacks Research estimates
• Positive Sentiment: Commercial growth remains supportive: Korlym sales rose 6.2% in the first half of 2026, while the launch of Lifyorli could diversify revenue beyond the company’s established Cushing’s syndrome treatment. Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
• Positive Sentiment: Institutional ownership is high and buying activity continues: Several funds added to or initiated positions during the second quarter, and institutions collectively own approximately 93.6% of outstanding shares. Analysts maintain a “Moderate Buy” consensus with an average price target of $138.17. Corcept Grows to Mid-Cap on Institutional Support
• Neutral Sentiment: Corcept’s latest reported quarter exceeded expectations, with earnings of $0.36 per share versus $0.02 expected and revenue of $256.15 million, up 31.7% year over year. However, the stock trades at a very elevated earnings multiple, increasing sensitivity to any slowdown or disappointing clinical and commercial developments.
• Negative Sentiment: Insiders have recently sold shares: Director James Wilson sold 10,000 shares for approximately $1.11 million, while Joseph Lyon sold 10,000 shares for about $1.13 million. Wilson retained a substantial stake, but Lyon’s sale reduced his position by roughly 63.8%, creating a modest sentiment overhang. Insider Selling at Corcept Therapeutics

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $114.86 on Friday. The company has a market cap of $12.42 billion, a P/E ratio of 273.48 and a beta of 0.45. The stock's fifty day moving average price is $108.19 and its two-hundred day moving average price is $74.96. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $126.38.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The company had revenue of $256.15 million during the quarter, compared to analysts' expectations of $221.15 million. During the same period in the previous year, the business earned $0.29 earnings per share. The firm's quarterly revenue was up 31.7% compared to the same quarter last year. On average, analysts expect that Corcept Therapeutics will post 2.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Corcept Therapeutics news, Director James Wilson sold 10,000 shares of the firm's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $110.69, for a total value of $1,106,900.00. Following the completion of the transaction, the director directly owned 1,064,543 shares of the company's stock, valued at $117,834,264.67. This trade represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 25,000 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $114.43, for a total transaction of $2,860,750.00. Following the transaction, the insider owned 9,755 shares of the company's stock, valued at $1,116,264.65. This trade represents a 71.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 446,119 shares of company stock worth $50,644,753. Company insiders own 20.70% of the company's stock.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC purchased a new position in Corcept Therapeutics during the second quarter worth about $645,000. Tidal Investments LLC raised its holdings in shares of Corcept Therapeutics by 9.2% in the 2nd quarter. Tidal Investments LLC now owns 24,218 shares of the biotechnology company's stock valued at $2,106,000 after acquiring an additional 2,039 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Corcept Therapeutics during the 2nd quarter valued at about $558,000. NewEdge Advisors LLC boosted its position in shares of Corcept Therapeutics by 17.9% during the 2nd quarter. NewEdge Advisors LLC now owns 11,041 shares of the biotechnology company's stock valued at $960,000 after acquiring an additional 1,677 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of Corcept Therapeutics by 568.4% during the second quarter. IFP Advisors Inc now owns 909 shares of the biotechnology company's stock worth $79,000 after purchasing an additional 773 shares in the last quarter. Institutional investors own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company's research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept's commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing's syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.